Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT04632992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04632992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 13, 2021
Completion date
February 27, 2024
Enrollment
252 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable or metastatic solid malignancy